UNSPSC 51111781: Olaparib

Olaparib is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.

UNSPSC 51111781 Olaparib, a Commodity code, does not reflect state and local government procurement activity in the recent opportunities dataset. Olaparib is a targeted cancer treatment pharmaceutical—a prescription drug subject to FDA approval and DEA scheduling where applicable—yet the recent state and local solicitations tagged under this code span emergency medical services supplies (BLS/ALS pharmaceuticals and naloxone distribution), long-term care facility pharmacy services, forensic drug reference standards, and EMS protocol software platforms. None of these opportunities involve procurement of olaparib itself or drugs in its therapeutic class. The mismatch suggests either miscoding in the state or local procurement system, or the code assignment reflects a data entry error rather than genuine pharmaceutical commodity procurement activity under this UNSPSC number.

The opportunities that do appear under this code—including the Tucson Fire Department's BLS/ALS pharmaceuticals and supplies solicitation (RFP 260217, due June 24, 2026), Dane County's long-term care facility pharmacy services (RFP 2026RFP061PR, due October 22, 2026), and West Texas Centers' prescription and pharmacy services (RFP RX1001, due August 21, 2026)—address managed pharmacy programs, distribution networks, and medical supply vending platforms rather than branded pharmaceutical products. No recent state or local procurement activity under UNSPSC 51111781 reflects actual demand for olaparib or similar oncology therapeutics at the state, county, municipal, or special-district level.